Coston McIsaac & Partners’s BioNTech BNTX Stock Holding History

Coston McIsaac & Partners’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20	Closed	-$1K	–	849
2026 Q1	$1K	Hold	20	–	–	﹤0.01%	783
2025 Q4	$1K	Hold	20	–	–	﹤0.01%	777
2025 Q3	$1K	Hold	20	–	–	﹤0.01%	748
2025 Q2	$2K	Hold	20	–	–	﹤0.01%	686
2025 Q1	$1K	Hold	20	–	–	﹤0.01%	708
2024 Q4	$2K	Hold	20	–	–	﹤0.01%	670
2024 Q3	$2K	Hold	20	–	–	﹤0.01%	681
2024 Q2	$1K	Hold	20	–	–	﹤0.01%	688
2024 Q1	$1K	Hold	20	–	–	﹤0.01%	678
2023 Q4	$2K	Hold	20	–	–	﹤0.01%	644
2023 Q3	$2K	Hold	20	–	–	﹤0.01%	643
2023 Q2	$2K	Hold	20	–	–	﹤0.01%	679
2023 Q1	$2K	Hold	20	–	–	﹤0.01%	673
2022 Q4	$3K	Hold	20	–	–	﹤0.01%	639
2022 Q3	$2K	Hold	20	–	–	﹤0.01%	594
2022 Q2	$3K	Buy	+20	New	+$3.06K	﹤0.01%	386

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Coston McIsaac & Partners's BNTX Position: Q2 2026 in Review

Coston McIsaac & Partners sold out of BioNTech (BNTX) in Q2 2026, closing a stake of 20 shares — an estimated $1K sold.

Coston McIsaac & Partners first reported a position in BNTX in Q2 2022 and held it in 16 quarters. The position peaked at $3K in Q4 2022. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Coston McIsaac & Partners reported no remaining BioNTech position as of Q2 2026 after selling out during the quarter.
Coston McIsaac & Partners sold 20 BioNTech shares in Q2 2026, an estimated $1K.
Coston McIsaac & Partners first reported a position in BioNTech in Q2 2022 and held it in 16 quarters.
Coston McIsaac & Partners's BioNTech position peaked at $3K in Q4 2022.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.